Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan (Unbekannt)
- Neue Suche nach: Chen, Yucherng
- Neue Suche nach: Nagaoka, Soshi
- Neue Suche nach: Katayose, Taeko
- Neue Suche nach: Sekine, Nobuyuki
- Neue Suche nach: Chen, Yucherng
- Neue Suche nach: Nagaoka, Soshi
- Neue Suche nach: Katayose, Taeko
- Neue Suche nach: Sekine, Nobuyuki
In:
Expert Opinion on Drug Safety
;
21
, 5
;
691-698
;
2022
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan
-
Beteiligte:Chen, Yucherng ( Autor:in ) / Nagaoka, Soshi ( Autor:in ) / Katayose, Taeko ( Autor:in ) / Sekine, Nobuyuki ( Autor:in )
-
Erschienen in:Expert Opinion on Drug Safety ; 21, 5 ; 691-698
-
Verlag:
- Neue Suche nach: Taylor & Francis
-
Erscheinungsdatum:04.05.2022
-
Format / Umfang:8 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Unbekannt
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 21, Ausgabe 5
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 585
-
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndromede Filippis, Renato / De Fazio, Pasquale / Kane, John M. / Schoretsanitis, Georgios et al. | 2022
- 589
-
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancerLau, David K. / Mencel, Justin / Chau, Ian et al. | 2022
- 599
-
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunityMotofei, Ion G. et al. | 2022
- 613
-
Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsCantini, Fabrizio / Goletti, Delia / Benucci, Maurizio / Foti, Rosario / Damiani, Arianna / Niccoli, Laura et al. | 2022
- 625
-
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?Vasileva, Svetlina S. / Tucker, Jack / Siskind, Dan / Eyles, Darryl et al. | 2022
- 641
-
Cardiac adverse effects of antiseizure medicationsZaccara, Gaetano / Lattanzi, Simona / Brigo, Francesco et al. | 2022
- 653
-
Safety considerations with the current treatments for peripheral T-cell lymphomaSethi, Tarsheen / Montanari, Francesca / Foss, Francine et al. | 2022
- 661
-
Anti-inflammatory strategies for atherosclerotic artery diseaseAgnello, Federica / Capodanno, Davide et al. | 2022
- 673
-
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated reviewDe Diego-Adeliño, Javier / Crespo, José Manuel / Mora, Fernando / Neyra, Adrián / Iborra, Pedro / Gutiérrez-Rojas, Luis / Salonia, Selman F. et al. | 2022
- 691
-
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in JapanChen, Yucherng / Nagaoka, Soshi / Katayose, Taeko / Sekine, Nobuyuki et al. | 2022
- 699
-
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionalsGeeven, Isa P. A. C. / Jessurun, Naomi T. / Wasylewicz, Arthur T. M. / Drent, Marjolein / Spuls, Phyllis I. / Hoentjen, Frank / van Puijenbroek, Eugène P. / Vonkeman, Harald E. / Grootens, Koen P. / van Doorn, Martijn B. A. et al. | 2022
- 707
-
Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysisSong, Weijuan / Shi, Lei / Wang, Yanhong / Zhang, Zisen et al. | 2022